Ideaya Biosciences Stock Price, News & Analysis

IDEAYA Biosciences (NASDAQ: IDYA), an oncology-focused precision medicine company, announced its selection for inclusion in the NASDAQ Biotechnology Index, effective prior to market open on December 21, 2020. This index tracks biotechnology and pharmaceutical securities on the NASDAQ and is recognized for its stringent criteria, including market value and share volume requirements. The inclusion may enhance IDEAYA's visibility and credibility in the market, potentially benefiting its stock performance.

IDEAYA Biosciences, Inc. (Nasdaq: IDYA) reported its Q3 2020 financial results, highlighting a cash position of $288.8 million, up from $100.5 million at the end of 2019. With collaboration revenue of $9.0 million, the company advances its synthetic lethality pipeline, including partnerships with GSK. Key updates include the IDE397 program targeting MAT2A, ongoing clinical trials for IDE196 in metastatic uveal melanoma, and strategic collaborations with Broad Institute and UCSD. The net loss for Q3 2020 was $4.9 million, significantly reduced from $11.0 million a year prior.

IDEAYA Biosciences (Nasdaq:IDYA), a precision medicine company focused on oncology, announced its participation in upcoming investor events. The company will present at the Stifel 2020 Healthcare Conference on November 16, 2020, at 1:00 pm PT, and hold a fireside chat at the Jefferies London Healthcare Conference on November 18, 2020, at 9:35 am PT. Live webcasts and subsequent replays will be available on IDEAYA's investor calendar page.

IDEAYA aims to develop targeted therapeutics using molecular diagnostics and biomarkers.

IDEAYA Biosciences (NASDAQ: IDYA) announced a strategic partnership with the Sellers Laboratory at the Broad Institute, focusing on target and biomarker discovery in oncology. Utilizing CRISPR technology, the collaboration aims to explore synthetic lethality in ovarian and breast cancer. IDEAYA's DECIPHER Dual CRISPR platform, developed with UC San Diego, is also highlighted, emphasizing ongoing evaluations of approximately 50,000 gene knockout combinations. The PARG program seeks a development candidate nomination in 2021, with a commitment to building a pipeline of first-in-class cancer therapeutics.

IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine company focusing on oncology, announced its participation in several investor relations events in September 2020. Key events include:

• JP Morgan CEO Series on September 8
• Citi 15th Annual BioPharma Conference on September 9
• RW Baird Global Health Care Conference on September 10
• H.C. Wainwright 22nd Annual Global Investment Conference on September 14
• Cantor Fitzgerald Global Healthcare Conference on September 17

Live webcasts of the events will be available on their website.

IDEAYA Biosciences, Inc. (IDYA) reported a transformative Q2 2020, with cash reserves of $172 million and an additional $127.5 million in gross proceeds to fund operations into 2024. The strategic partnership with GSK offers up to $3 billion in milestone opportunities across pipeline programs. Key developments include the nomination of IDE397 for MAT2A and progress on IDE196 in clinical trials. R&D expenses decreased slightly to $8.6 million, while G&A expenses increased to $4 million, contributing to a net loss of $12.4 million.

IDEAYA Biosciences (Nasdaq: IDYA) announced the effectiveness of its strategic partnership with GlaxoSmithKline (GSK) after receiving clearance under the Hart-Scott-Rodino Act. This collaboration includes an upfront cash payment of $100 million and focuses on Synthetic Lethality programs. Additionally, IDEAYA closed a direct private placement equity financing with Glaxo Group, raising approximately $20 million by selling 1,333,333 shares at $15.00 each. IDEAYA expects sufficient funds to support operations into 2024.

IDEAYA Biosciences (Nasdaq: IDYA) announced the achievement of clinical protocol criteria for cohort expansion in the Phase 2 basket trial of IDE196 targeting melanoma patients with GNAQ or GNA11 mutations. The trial has enrolled 5 patients, including 1 with a confirmed partial response. If further responses are observed, an additional 15 patients may join, bringing total enrollment to 24. IDEAYA anticipates interim data for IDE196 monotherapy in early 2021, while the impact of Covid-19 on trials is being monitored.

IDEAYA Biosciences (Nasdaq: IDYA) announced its participation in two investor conferences in August 2020. CEO Yujiro S. Hata will engage in a fireside chat at the BTIG Virtual Biotechnology Conference on August 11 at 1:00 pm EST. He will also participate in the Wedbush PacGrow Healthcare Virtual Conference on August 12 at 8:00 am EST, discussing his recent report on synthetic lethality in cancer. Live webcasts will be available on IDEAYA's website, with replays accessible for 30 days afterward.